These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 27181081)
1. Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study. Elsayed M; Kobayashi D; Kubota T; Matsunaga N; Murata R; Yoshizawa Y; Watanabe N; Matsuura T; Tsurudome Y; Ogino T; Ohdo S; Shimazoe T Biol Pharm Bull; 2016 Aug; 39(8):1238-46. PubMed ID: 27181081 [TBL] [Abstract][Full Text] [Related]
2. Isoprenoids responsible for protein prenylation modulate the biological effects of statins on pancreatic cancer cells. Gbelcová H; Rimpelová S; Knejzlík Z; Šáchová J; Kolář M; Strnad H; Repiská V; D'Acunto WC; Ruml T; Vítek L Lipids Health Dis; 2017 Dec; 16(1):250. PubMed ID: 29262834 [TBL] [Abstract][Full Text] [Related]
3. Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells. Fujita M; Tohi M; Sawada K; Yamamoto Y; Nakamura T; Yagami T; Yamamori M; Okamura N Oncol Rep; 2012 May; 27(5):1371-6. PubMed ID: 22322451 [TBL] [Abstract][Full Text] [Related]
4. Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Baulch-Brown C; Molloy TJ; Yeh SL; Ma D; Spencer A Leuk Res; 2007 Mar; 31(3):341-52. PubMed ID: 16996129 [TBL] [Abstract][Full Text] [Related]
5. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status. Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179 [TBL] [Abstract][Full Text] [Related]
6. Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins. Yu R; Longo J; van Leeuwen JE; Mullen PJ; Ba-Alawi W; Haibe-Kains B; Penn LZ Cancer Res; 2018 Mar; 78(5):1347-1357. PubMed ID: 29229608 [TBL] [Abstract][Full Text] [Related]
7. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Kotamraju S; Williams CL; Kalyanaraman B Cancer Res; 2007 Aug; 67(15):7386-94. PubMed ID: 17671209 [TBL] [Abstract][Full Text] [Related]
8. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay. Knight LA; Kurbacher CM; Glaysher S; Fernando A; Reichelt R; Dexel S; Reinhold U; Cree IA BMC Cancer; 2009 Jan; 9():38. PubMed ID: 19175937 [TBL] [Abstract][Full Text] [Related]
9. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Nagashima T; Okazaki H; Yudoh K; Matsuno H; Minota S Arthritis Rheum; 2006 Feb; 54(2):579-86. PubMed ID: 16447234 [TBL] [Abstract][Full Text] [Related]
10. Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Bocci G; Fioravanti A; Orlandi P; Bernardini N; Collecchi P; Del Tacca M; Danesi R Br J Cancer; 2005 Aug; 93(3):319-30. PubMed ID: 16052215 [TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells. Göbel A; Thiele S; Browne AJ; Rauner M; Zinna VM; Hofbauer LC; Rachner TD Cancer Lett; 2016 May; 375(1):162-171. PubMed ID: 26968247 [TBL] [Abstract][Full Text] [Related]
12. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872 [TBL] [Abstract][Full Text] [Related]
13. Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model. Vintonenko N; Jais JP; Kassis N; Abdelkarim M; Perret GY; Lecouvey M; Crepin M; Di Benedetto M Mol Pharmacol; 2012 Sep; 82(3):521-8. PubMed ID: 22723339 [TBL] [Abstract][Full Text] [Related]
14. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. Caraglia M; Marra M; Leonetti C; Meo G; D'Alessandro AM; Baldi A; Santini D; Tonini G; Bertieri R; Zupi G; Budillon A; Abbruzzese A J Cell Physiol; 2007 May; 211(2):533-43. PubMed ID: 17192846 [TBL] [Abstract][Full Text] [Related]
15. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway. Honda Y; Takahashi S; Zhang Y; Ono A; Murakami E; Shi N; Kawaoka T; Miki D; Tsuge M; Hiraga N; Abe H; Ochi H; Imamura M; Aikata H; Chayama K J Gastroenterol Hepatol; 2015 Mar; 30(3):619-27. PubMed ID: 25167891 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631 [TBL] [Abstract][Full Text] [Related]